Navigation Links
Discovery suggests new combination therapy strategy for basal-like breast cancers
Date:5/21/2012

CHAPEL HILL, N.C. Multiple research projects including a 2006 study conducted at the University of North Carolina at Chapel Hill have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple negative breast cancer, is more prevalent in African Americans than their Caucasian counterparts.

A new study led by UNC Lineberger scientist Charles Perou, PhD, and Sean Egan, PhD, from The Hospital for Sick Children in Toronto, Ontario, demonstrates that deletion of a sugar transferase called LFNG (nicknamed "lunatic fringe"), promotes cell proliferation and tumor formation of basal-like breast cancers. The study was published last week in the journal Cancer Cell.

In a laboratory model, the deletion of LFNG not only caused tumors to form but also activated two cellular signaling pathways thought to be important in tumor formation. The team found increased activation of both notch signaling (a receptor found on the surface of cells that is involved in stem cell differentiation and development) and increased expression of the Met oncogene.

Taking the laboratory model a step further, the team examined these same genes and signaling pathways in basal-like tumors and found the same genetic signature.

"This is exciting because there are drugs in development that target each of these pathways. While targeting each pathway alone might work, our findings suggest that combination therapy could be a promising strategy for treating these basal-like tumors," says Dr. Perou, who is the May Goldman Shaw Distinguished Professor of Molecular Oncology and professor of genetics, and pathology and laboratory medicine at the UNC School of Medicine.

Basal-like breast cancer tends to be more aggressive and have a poorer prognosis than other types, making up about 15 percent of all breast cancers. In young African-American women who develop breast cancer, the subtype makes up about 39 percent of all diagnoses. It is primarily treated with chemotherapy, although newer targeted drugs are being tested in clinical trials.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina Health Care
Source:Eurekalert

Related medicine news :

1. Researchers make promising discovery in pursuit of effective lymphoma treatments
2. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
3. H1N1 discovery paves way for universal flu vaccine: UBC research
4. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
5. Discovery could help to develop drugs for organ transplant and cancer patients
6. Washingtons Life Sciences Discovery Fund awards commercialization grants
7. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
8. New discovery of proteins involved in positioning muscular nuclei
9. Cell signaling discovery provides new hope for blood disorders
10. Gene mutation discovery sparks hope for effective endometriosis screening
11. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: